University of Colorado Denver Anschutz Medical Campus, Aurora.
J Infect Dis. 2013 Nov 1;208(9):1386-90. doi: 10.1093/infdis/jit342. Epub 2013 Aug 1.
Prevaccination and 6-week postvaccination samples from the immunogenicity substudy (n = 2269) of the zoster vaccine (ZV) efficacy trial (N = 22 439) in 50-59-year-old subjects were examined for varicella-zoster virus-specific antibody responses to vaccination. The varicella-zoster virus geometric mean titer (GMT) and geometric mean fold rise were higher in ZV recipients than in placebo recipients (GMT, 660.0 vs 293.1 glycoprotein enzyme-linked immunosorbent assay units/mL [P < .001], respectively; geometric mean fold rise, 2.31 vs 1.00 [P < .025]). In each group there was a strong inverse correlation between postvaccination GMT and risk of subsequent herpes zoster. Although these data provide strong evidence that relates ZV-induced antibody and the risk of herpes zoster, a protective threshold was not determined. Clinical Trials Registration. NCT00534248.
在带状疱疹疫苗(ZV)疗效试验(N=22439)的免疫原性子研究中,对 50-59 岁受试者的预接种和 6 周后接种样本(n=2269)进行了水痘带状疱疹病毒特异性抗体反应检测。与安慰剂组相比,ZV 组的水痘带状疱疹病毒几何平均滴度(GMT)和几何平均倍数升高更高(GMT,660.0 对 293.1 糖蛋白酶联免疫吸附试验单位/ml[P<0.001];几何平均倍数升高,2.31 对 1.00[P<0.025])。在每组中,接种后 GMT 与随后发生带状疱疹的风险之间存在很强的负相关关系。尽管这些数据提供了与 ZV 诱导的抗体和带状疱疹风险相关的强有力证据,但未确定保护阈值。临床试验注册。NCT00534248。